May 12, 2022
Ono Pharmaceutical’s group revenue in FY2021 through this March jumped 16.8% over the prior year to 361.4 billion yen thanks to strong performances delivered by the PD-1 inhibitor Opdivo (nivolumab) and SGLT2 inhibitor Forxiga (dapagliflozin). It expects to break the...read more